O

OmniAb Inc
NASDAQ:OABI

Watchlist Manager
OmniAb Inc
NASDAQ:OABI
Watchlist
Price: 1.88 USD -4.08%
Market Cap: $270.6m

Operating Margin

-342.3%
Current
Declining
by 111.6%
vs 3-y average of -230.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-342.3%
=
Operating Income
$-72.2m
/
Revenue
$21.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-342.3%
=
Operating Income
$-72.2m
/
Revenue
$21.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
OmniAb Inc
NASDAQ:OABI
270.6m USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
233.5B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.5B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.9T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.9B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.1B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.2B EUR
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 14 112 companies
10th percentile
-342.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

OmniAb Inc
Glance View

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
1.19 USD
Overvaluation 37%
Intrinsic Value
Price
O
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-342.3%
=
Operating Income
$-72.2m
/
Revenue
$21.1m
What is OmniAb Inc's current Operating Margin?

The current Operating Margin for OmniAb Inc is -342.3%, which is below its 3-year median of -230.7%.

How has Operating Margin changed over time?

Over the last 3 years, OmniAb Inc’s Operating Margin has decreased from -104.5% to -342.3%. During this period, it reached a low of -396.8% on Mar 31, 2024 and a high of -40.5% on Mar 31, 2023.

Back to Top